Citius Oncology, Inc. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-26: Disclosure Insider Trading Policies Proc Adopted; Period 2024-10-01..2025-09-30; Value Yes.
- 2026-08-26: Disclosure Restatement Does Not Require Recovery; Qualifiers RestatementDate: 2025-09-30; Period 2024-10-01..2025-09-30; Value We have adopted a clawback policy to provide for the recovery of erroneously-awarded incentive compensation, as required by the Dodd-Frank Act, final SEC rules and applicable listing standards..
- 2026-08-26: Disclosure Award Timing MNPI Disclosure; Period 2024-10-01..2025-09-30; Value Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information While we do not have a formal written policy in place with regard to the timing of awards of options or similar awards in relation to the disclosure of material nonpubl….
- 2026-08-26: Disclosure Award Timing Method; Period 2024-10-01..2025-09-30; Value While we do not have a formal written policy in place with regard to the timing of awards of options or similar awards in relation to the disclosure of material nonpublic information, our equity awards are generally granted on fixed dates determined in advance. On limited occasions, our Compensation….
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-26 DEF 14A | Insider Trading Policies Proc Adopted | 2024-10-01..2025-09-30 | Yes | |
| 2026-08-26 DEF 14A | Restatement Does Not Require Recovery | RestatementDate: 2025-09-30 | 2024-10-01..2025-09-30 | We have adopted a clawback policy to provide for the recovery of erroneously-awarded incentive compensation, as required by the Dodd-Frank Act, final SEC rules and applicable listing standards. |
| 2026-08-26 DEF 14A | Award Timing MNPI Disclosure | 2024-10-01..2025-09-30 | Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information While we do not have a formal written policy in place with regard to the timing of awards of options or similar awards in relation to the disclosure of material nonpubl… | |
| 2026-08-26 DEF 14A | Award Timing Method | 2024-10-01..2025-09-30 | While we do not have a formal written policy in place with regard to the timing of awards of options or similar awards in relation to the disclosure of material nonpublic information, our equity awards are generally granted on fixed dates determined in advance. On limited occasions, our Compensation… | |
| 2026-08-26 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2024-10-01..2025-09-30 | No | |
| 2026-08-26 DEF 14A | Award Timing Predetermined | 2024-10-01..2025-09-30 | Yes | |
| 2026-08-26 DEF 14A | Award Timing How MNPI Considered | 2024-10-01..2025-09-30 | The Compensation Committee approves all equity award grants on or before the grant date and does not grant equity awards in anticipation of the release of material nonpublic information. Similarly, the Compensation Committee does not time the release of material nonpublic information based on equity… | |
| 2026-08-26 DEF 14A | Award Timing MNPI Considered | 2024-10-01..2025-09-30 | No | |
| 2026-08-14 10-Q | Non Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Non Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-08-14 10-Q | Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-05-15 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-15 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-15 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-15 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-02-13 10-Q | Non Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-02-13 10-Q | Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-02-13 10-Q | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-02-13 10-Q | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2025-12-23 10-K | Non Rule10b51Arr Terminated | 2024-10-01..2025-09-30 | No | |
| 2025-12-23 10-K | Rule10b51Arr Terminated | 2024-10-01..2025-09-30 | No | |
| 2025-12-23 10-K | Non Rule10b51Arr Adopted | 2024-10-01..2025-09-30 | No | |
| 2025-12-23 10-K | Rule10b51Arr Adopted | 2024-10-01..2025-09-30 | No | |
| 2025-09-26 DEF 14A | Insider Trading Policies Proc Adopted | 2023-10-01..2024-09-30 | Yes | |
| 2025-09-26 DEF 14A | Restatement Does Not Require Recovery | RestatementDate: 2024-09-30 | 2023-10-01..2024-09-30 | We have adopted a clawback policy to provide for the recovery of erroneously-awarded incentive compensation, as required by the Dodd-Frank Act, final SEC rules and applicable listing standards. |
| 2025-09-26 DEF 14A | Award Timing MNPI Disclosure | 2023-10-01..2024-09-30 | Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information While we do not have a formal written policy in place with regard to the timing of awards of options or similar awards in relation to the disclosure of material nonpubl… | |
| 2025-09-26 DEF 14A | Award Timing Method | 2023-10-01..2024-09-30 | While we do not have a formal written policy in place with regard to the timing of awards of options or similar awards in relation to the disclosure of material nonpublic information, our equity awards are generally granted on fixed dates determined in advance. On limited occasions, our Compensation… | |
| 2025-09-26 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2023-10-01..2024-09-30 | No | |
| 2025-09-26 DEF 14A | Award Timing Predetermined | 2023-10-01..2024-09-30 | Yes | |
| 2025-09-26 DEF 14A | Award Timing How MNPI Considered | 2023-10-01..2024-09-30 | The Committee approves all equity award grants on or before the grant date and does not grant equity awards in anticipation of the release of material nonpublic information. Similarly, the Committee does not time the release of material nonpublic information based on equity award grant dates. | |
| 2025-09-26 DEF 14A | Award Timing MNPI Considered | 2023-10-01..2024-09-30 | No | |
| 2025-08-12 10-Q | Non Rule10b51Arr Adopted | 2025-04-01..2025-06-30 | No | |
| 2025-08-12 10-Q | Rule10b51Arr Adopted | 2025-04-01..2025-06-30 | No | |
| 2025-08-12 10-Q | Rule10b51Arr Terminated | 2025-04-01..2025-06-30 | No | |
| 2025-08-12 10-Q | Non Rule10b51Arr Terminated | 2025-04-01..2025-06-30 | No | |
| 2025-05-14 10-Q | Non Rule10b51Arr Adopted | 2025-01-01..2025-03-31 | No | |
| 2025-05-14 10-Q | Rule10b51Arr Adopted | 2025-01-01..2025-03-31 | No | |
| 2025-05-14 10-Q | Rule10b51Arr Terminated | 2025-01-01..2025-03-31 | No | |
| 2025-05-14 10-Q | Non Rule10b51Arr Terminated | 2025-01-01..2025-03-31 | No | |
| 2025-02-14 10-Q | Non Rule10b51Arr Adopted | 2024-10-01..2024-12-31 | No | |
| 2025-02-14 10-Q | Rule10b51Arr Adopted | 2024-10-01..2024-12-31 | No | |
| 2025-02-14 10-Q | Rule10b51Arr Terminated | 2024-10-01..2024-12-31 | No | |
| 2025-02-14 10-Q | Non Rule10b51Arr Terminated | 2024-10-01..2024-12-31 | No | |
| 2024-12-27 10-K | Non Rule10b51Arr Terminated | 2024-07-01..2024-09-30 | No | |
| 2024-12-27 10-K | Rule10b51Arr Terminated | 2024-07-01..2024-09-30 | No | |
| 2024-12-27 10-K | Non Rule10b51Arr Adopted | 2024-07-01..2024-09-30 | No | |
| 2024-12-27 10-K | Rule10b51Arr Adopted | 2024-07-01..2024-09-30 | No |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |